Home › Research › Topics › anti-amyloid
anti-amyloid
332 studies tagged anti-amyloid, dated 2000 to 2026-09-09. Bibliography: BibTeX (.bib) · RIS (.ris)
Newest in this topic
Studies
332 studies carry this tag.
Date range
2000 to 2026
Top journals
- Alzheimer's & dementia : the journal of the Alzheimer's Association 26
- Journal of Alzheimer's disease : JAD 21
- The journal of prevention of Alzheimer's disease 20
- Alzheimer's research & therapy 18
- Alzheimer's & dementia (New York, N. Y.) 14
148 journals in all.
Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.
-
Alzheimer's disease, the leading cause of dementia, is defined by extracellular amyloid‑β (Aβ) plaques, intracellular tau aggregates and neurodegeneration.
-
Amyloid-related imaging abnormalities (ARIA) occurred in 11.2% (10/89) with lecanemab and 13.3% (11/83) with donanemab-less than in pivotal trials.
-
ARIA-E incidence was 2.0% in non-carriers and 6.2% in εε4/εε4 homozygotes (εε4/εε4-versus-non-carrier OR 3.25, versus 8.49 in Clarity AD and 8.32 in Japan post-marketing surveillance).
-
Six trials (3103 Gantenerumab significantly reduces amyloid and statistically improves select functional (FAQ) and cognitive (ADAS-Cog13) measures in early AD; however, these changes remain below accepted MCID thresholds, indicating a lack of true clinical meaningfulness.
-
Centiloid values significantly decreased from 52.3 ± 23.4 at baseline to - 5.6 ± 16.5 at follow-up, with a mean change of - 58.0 (p < 0.001).
-
Data collection started on June 3, 2026, and is planned to close on June 30, 2026.
-
Temporal imaging variables may provide independent prognostic information beyond baseline risk, supporting a dynamic model of haemorrhagic risk in Alzheimer’s disease.
-
Donanemab-mediated slowing of disease progression occurred across baseline tau PET and plasma P-tau217 levels.
-
The recent advent of anti-amyloid-β monoclonal antibodies has introduced new demands for MRI-based screening of amyloid-related imaging abnormalities, particularly the hemorrhage subtype (ARIA-H).
-
Lecanemab is an anti-amyloid monoclonal antibody, recently approved in the UK as a treatment for mild cognitive impairment (MCI) and mild dementia due to Alzheimer's disease (AD) in adults who are apolipoprotein E ε4 gene (APOE4) heterozygotes or non-carriers.A group of UK neurologists, old age psychiatrists and geriatricians with expertise in AD convened to agree appropriate use recommendations for lecanemab in UK clinical practice.
-
The mean age was 74.2 ± 7.9 years, and 89 (74%) were female.
-
Alzheimer's disease (AD) is a progressive neurodegenerative disorder marked by cognitive decline and functional impairment, primarily driven by the accumulation of amyloid-beta (Aβ) plaques and tau tangles.
-
ARIA were infrequent. In donanemab-treated patients, mildly symptomatic ARIA-E occurred in 10% (2/20) and asymptomatic ARIA-H in 15% (3/20).
-
Alzheimer's disease (AD) remains the leading cause of dementia in Europe, with limited therapeutic options despite decades of research.
-
Lecanemab significantly attenuated cognitive decline versus ADNI.
-
1795 participants with early AD were enrolled in Clarity AD, of which 1521 were ApoE ε4 heterozygotes or non-carriers (85 %).
-
The introduction of anti-amyloid monoclonal antibodies marks a major shift in Alzheimer's disease (AD) care, moving treatment toward biological modification and reshaping diagnostic and organizational models.
-
619 Colombian API registrants were prescreened, 315 were assessed for eligibility, and 252 were enrolled (crenezumab-carrier, n=85; placebo-carrier, n=84; placebo-non-carrier, n=83; 160 [63%] women and 92 [37%] men) between Dec 20, 2013, and Feb 27, 2017. 237 (94%) completed the trial, with final data collection on March 22, 2022.
-
The incremental cost of the lecanemab group compared to the aducanumab group was $30,018.97, with an increase in quality-adjusted life-years (QALYs) of 0.25, resulting in an ICER of $121,678.49 per QALY gained.
-
The overall incidence of any ARIA was 25.2%, with ARIA-H occurring in 22.4% of patients and ARIA-E in 12.2%.
-
In 2025, several major advances have marked the field of neurology.
-
47/100
Alzheimer's disease (AD) is a progressive neurodegenerative disorder marked by decreased amyloid-beta (Aβ) clearance, enhanced Aβ aggregation, an increased risk of amyloid-related imaging abnormalities (ARIA), and blood-brain barrier (BBB) dysfunction.
-
BackgroundLecanemab and donanemab are anti-amyloid-β monoclonal antibodies recently approved in the United States and Europe for the treatment of early Alzheimer's disease (AD).
-
43/100
Nanobodies (single-domain antibodies, VHHs) have emerged as versatile tools for evaluating and treating Alzheimer's disease (AD).
-
BackgroundLecanemab reduces amyloid levels and modestly slows cognitive decline in a large cohort of early Alzheimer's disease (AD) but lacks real-world safety data in Chinese population.
-
The efficacy and safety of anti-amyloid mAbs in AD may differ based on patients' demographic and genetic factors.
-
Lecanemab was generally well tolerated by most patients with early AD and treatment appeared to be more effective and safer in patients with low CSF-ptau181 levels.
-
Alzheimer's disease (AD) is characterized by the accumulation of amyloid beta, which is strongly associated with disease progression and cognitive decline.
-
The mean age was 66 years (65.53 ± 9.31), and 51 (67.1%) participants being female.
-
The occurrence of amyloid-related imaging abnormalities (ARIA), found in clinical trials for Aβ-immunotherapy, has been related to the antibody’s effector function on glial activation by the Fc portion of the antibody.
-
Prevention of Alzheimer disease (AD) is a medical challenge owing to its complex pathogenesis, which involves amyloid-β (Aβ) and tau aggregation, neuroinflammation and progressive neurodegeneration.
-
Among 1005 amyloid-positive participants, 24.6% were eligible for lecanemab and 28.0% for donanemab (9.1% and 10.3% of the initial sample).
-
The past several decades have yielded deeper insights into the multifactorial pathogenesis and intervention strategies of Alzheimer's disease (AD).
-
Alzheimer's disease (AD) is a progressive neurodegenerative disorder affecting millions worldwide, and with advancements in the medical field, Anti-amyloid monoclonal antibodies (AA mAbs) targeting amyloid-β have emerged as potential disease-modifying agents altering AD pathology.
-
Alzheimer's disease (AD) is a progressive neurodegenerative disorder pathologically characterized by the accumulation of amyloid-beta (Aβ) and neurofibrillary tangles of hyperphosphorylated tau in the brain.
-
16/100
Our study examined the safety and tolerability of centralized lecanemab administration across a widely distributed region and suggests that use of distributed infusion sites increases access to disease-modifying treatment without significant increase in risk.
-
These findings support the short-term efficacy and safety of Lecanemab in early AD and highlight plasma biomarkers as a treatment-responsive biomarker.
-
CAARS has the potential to predict CAA severity; however, its clinical utility should be evaluated in follow-up studies.
-
These findings support further investigation of ABvac40 as a potential disease-modifying therapy.
-
Anti-amyloid monoclonal antibodies have finally achieved their translational breakthrough after many years of unmet expectations.
-
The complete absence of ARIA distinguishes XPro1595 from amyloid-targeting therapies and supports its potential for use in combination strategies and potentially for those at a higher risk of ARIA.
-
Alzheimer's disease (AD) remains one of the most pressing neurodegenerative disorders worldwide, with increasing prevalence and limited disease-modifying treatments.
-
41/100
However, these therapies are associated with amyloid-related imaging abnormalities (ARIA), particularly in individuals carrying the APOE ε4 allele, necessitating close monitoring and individualized risk assessment.
-
Anti-amyloid mAbs consistently demonstrated robust amyloid clearance and modest slowing of clinical decline in early symptomatic AD.
-
Alzheimer's disease is a major cause of dementia, that affects approximately 7-8% of people aged 65 years and older (according to WHO & Alzheimer's Disease International) and thus is a major concern in public health world-wide.
-
91/100
55-80 years of age were screened (N = 63,124).
-
BackgroundDonanemab, a monoclonal antibody targeting amyloid-β (Aβ) plaques, has shown the ability to reduce cerebral amyloid burden in early Alzheimer's disease (AD).
-
43/100
We retrospectively reviewed 20 consecutive patients with Alzheimer's disease who switched from lecanemab to donanemab.
-
43/100
Alzheimer's disease (AD), referred to as a type of dementia, is a progressive neurodegenerative disease with cognitive decline and key features comprising extracellular amyloid-β(Aβ) and intracellular neurofibrillary tangles.
-
Donanemab (Kisunla) is a humanized IgG1 monoclonal antibody specifically targeting a modified form of β-amyloid found predominantly within plaques (characterized as N-terminal pyroglutamate Aβ).
From across this tag
7 of the 332 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 7. The same 7 appear here every time.
- Lecanemab: Appropriate Use Recommendations by Korean Dementia Association
- Regional effects of gantenerumab on neuroimaging biomarkers in the DIAN-TU-001 trial
- Aducanumab: a new phase in therapeutic development for Alzheimer’s disease?
- Bispecific brain-penetrant antibodies for treatment of Alzheimer's disease
- Alzheimer's disease: treatments in discovery and development
- caso de aducanumab ¿Más esperanza que ciencia?
- Alzheimer's disease drug development pipeline: 2019